Get started

Sanofi

Sanofi can ShineSanofi India Ltd. engages in the manufacturing and distribution of pharmaceutical drugs. It focuses on the following therapeutic areas: diabetes, cardiology, consumer healthcare, hospitals, central nervous system, and antihistamines. Sanofi India Ltd. CMP is 7048.85. The positive aspects of the company are Company with No Debt, Company with Zero Promoter Pledge, Mutual Funds Increased Shareholding over the Past Two Months. The Negative aspects of the company are high Valuation (P.E. = 30.7), Stocks Underperforming their Industry Price Change in the Quarter, Declining profits every quarter for the past 3 quarters and Increasing Trend in Non-Core Income. Entry can be taken after closing above 7066 Targets in the stock will be 7304 and 7434. The long-term target in the stock will be 7618. Stop loss in the stock should be maintained at Closing below 6679 or 6300 depending on your risk taking ability. Disclaimer: The above information is provided for educational purpose, analysis and paper trading only. Please don't treat this as a buy or sell recommendation for the stock. We do not guarantee any success in highly volatile market or otherwise. Stock market investment is subject to market risks which include global and regional risks. We will not be responsible for any Profit or loss that may occur due to any financial decision taken based on any data provided in this message.
NSE:SANOFILong
by Happy_Candles_Investment
Sanofi (SNY): A Strong Investment CaseCompany Overview: Sanofi NASDAQ:SNY is a major pharmaceutical company based in Paris, with a market capitalization of $134 billion. Investment Highlights: Dividend Yield: 3.8%, more than double the S&P 500 average. Drug Portfolio: Diverse and includes successful drug developments. Pipeline: Promising future drug pipeline with potential for growth. Berkshire Hathaway Investment: Long-standing investment from Berkshire Hathaway underscores the company’s attractiveness and stability. Outlook: We are bullish on SNY due to its growth potential and solid dividend payout. The combination of a strong drug portfolio, promising pipeline, and robust dividend makes Sanofi a compelling investment choice. #Sanofi #SNY #Pharmaceuticals #Investment #DividendYield #MarketCap #GrowthPotential #BerkshireHathaway #StockAnalysis #Bullish
NASDAQ:SNYLong
by Richtv_official
Is Sanofi Undervalue by 22% ?I wanted to share an analysis I've conducted on Sanofi over the past five years using both comparable methods and a 2-Stage DCF approach. According to my findings, the market value appears to be at least 22% undervalued in comparison with its fair value. Moreover, considering the post-COVID effects on pharmaceutical companies, I believe Sanofi presents a compelling opportunity to purchase its stock with potentially lower risk. I would be glad to share my detailed analysis for any one interested in more in debt explorations Disclaimer: This information is based on my personal analysis and is not to be considered financial advice. I am expressing my own views and opinions on the current market conditions and Sanofi's stock. Always conduct your own research and consider seeking advice from a qualified financial professional before making any investment decisions.
EURONEXT:SANLong
by arya1992
Key levels for SANOFIThe algorithm is showing a very profitable pattern in SANOFI. First, if the price breaks up we have a clear rally until the top of the channel with a tight stop loss slightly below the break point. On the other hand, if the market is moving down, we should see a break to the downside of the channel, then an easy break of the support and the blue line would be the last support before we see a major correction to 83$, where 3 different patterns are pointing out as a clear support area where demand will come back. Good luck!
EURONEXT:SAN
by TopChartPatterns
#ASTERDM #BAJAJHCARE #MAXHEALTH #LAURUSLABS #NATCOPHARMA #GLAND #ASTERDM NSE: ASTERDM CMP: 225 TP: 300 SL: 200 TF: <6m RR > ~3 times Return > 33% THYROCARE CNXPHARMA LUPIN SUNPHARMA SPARC DIVISLAB DRREDDY AUROPHARMA BALPHARMA GLENMARK SANOFI PFIZER BPLPHARMA MARKSANS BIOCON GRANULES IPCALAB LAURUSLABS NATCOPHARM GLAND ALKEM ZYDUSLIFE APOLLOHOSP FORTIS AARTIDRUGS ZYDUSWELL MAXHEALTH BAJAJHCARE Factors: BULLISH WEDGE BREAKOUT Trend Following Rising Volume with rising Prices. Flag pattern breakout. Pennant Pattern Breakout with Bullish Candle. Retest Successful. Higher Highs & Higher Lows. Broken above RESISTANCE levels Trading at SUPPORT levels Earnings are strong. Bullish Wedge Breakout Risk Return Ratio is healthy. And Rising from Double Bottom Pattern to Flag Pattern forming. If you like my work KINDLY LIKE SHARE & FOLLOW this page for free Stock Recommendations. With 💚 from Rachit Sethia
NSE:ASTERDMLong
by Rachit_Sethia
#LUPIN #LAURUSLABS #ZYDUSLIFE #APOLLOHOSP #FORTIS #AARTIDRUGS #I#LUPIN NSE: LUPIN CMP: 756 TP: 910 SL: 700 TF: <6m RR > 3 times Return > 20% THYROCARE CNXPHARMA LUPIN NSE:CIPLA SUNPHARMA SPARC DIVISLAB DRREDDY AUROPHARMA BALPHARMA GLENMARK SANOFI PFIZER BPLPHARMA MARKSANS BIOCON GRANULES IPCALAB LAURUSLABS NATCOPHARM GLAND ALKEM ZYDUSLIFE APOLLOHOSP FORTIS AARTIDRUGS Factors: BULLISH WEDGE BREAKOUT Trend Following Rising Volume with rising Prices. Flag pattern breakout. Pennant Pattern Breakout with Bullish Candle. Retest Successful. Higher Highs & Higher Lows. Broken above RESISTANCE levels Trading at SUPPORT levels Earnings are strong. Bullish Wedge Breakout Risk Return Ratio is healthy. And Rising from Double Bottom Pattern to Flag Pattern forming. If you like my work KINDLY LIKE SHARE & FOLLOW this page for free Stock Recommendations. With 💚 from Rachit Sethia
NSE:LUPINLong
by Rachit_Sethia
#AUROPHARMA #CIPLA #DIVISLAB #DRREDDY #LUPIN #GLENMARK #PFIZER #AUROPHARMA NSE: AUROPHARMA CMP: 437 TP: 535 SL: 400 TF: <6m RR > 3.5 times Return > 22% THYROCARE CNXPHARMA LUPIN NSE:CIPLA SUNPHARMA SPARC DIVISLAB DRREDDY AUROPHARMA BALPHARMA GLENMARK SANOFI PFIZER Factors: BULLISH WEDGE BREAKOUT Trend Following Rising Volume with rising Prices. Flag pattern breakout. Pennant Pattern Breakout with Bullish Candle. Retest Successful. Higher Highs & Higher Lows. Broken above RESISTANCE levels Trading at SUPPORT levels Earnings are strong. Bullish Wedge Breakout Risk Return Ratio is healthy. And Rising from Double Bottom Pattern to Flag Pattern forming. If you like my work KINDLY LIKE SHARE & FOLLOW this page for free Stock Recommendations. With 💚 from Rachit Sethia
NSE:AUROPHARMALong
by Rachit_Sethia
2
Sanofi found support at previous resistance.Sanofi - 30d expiry - We look to Buy a break of 88.01 (stop at 84.48) Previous resistance level of 88 broken. Our short term bias remains positive. Previous resistance, now becomes support at 88. 50 1day EMA is at 86.97. Support is located at 88 and should stem dips to this area. Daily signals are mildly bullish. Our profit targets will be 96.72 and 97.72 Resistance: 91.00 / 92.90 / 95.00 Support: 90.00 / 88.00 / 86.20 Disclaimer – Saxo Bank Group. Please be reminded – you alone are responsible for your trading – both gains and losses. There is a very high degree of risk involved in trading. The technical analysis , like any and all indicators, strategies, columns, articles and other features accessible on/though this site (including those from Signal Centre) are for informational purposes only and should not be construed as investment advice by you. Such technical analysis are believed to be obtained from sources believed to be reliable, but not warrant their respective completeness or accuracy, or warrant any results from the use of the information. Your use of the technical analysis , as would also your use of any and all mentioned indicators, strategies, columns, articles and all other features, is entirely at your own risk and it is your sole responsibility to evaluate the accuracy, completeness and usefulness (including suitability) of the information. You should assess the risk of any trade with your financial adviser and make your own independent decision(s) regarding any tradable products which may be the subject matter of the technical analysis or any of the said indicators, strategies, columns, articles and all other features. Please also be reminded that if despite the above, any of the said technical analysis (or any of the said indicators, strategies, columns, articles and other features accessible on/through this site) is found to be advisory or a recommendation; and not merely informational in nature, the same is in any event provided with the intention of being for general circulation and availability only. As such it is not intended to and does not form part of any offer or recommendation directed at you specifically, or have any regard to the investment objectives, financial situation or needs of yourself or any other specific person. Before committing to a trade or investment therefore, please seek advice from a financial or other professional adviser regarding the suitability of the product for you and (where available) read the relevant product offer/description documents, including the risk disclosures. If you do not wish to seek such financial advice, please still exercise your mind and consider carefully whether the product is suitable for you because you alone remain responsible for your trading – both gains and losses.
EURONEXT:SANLong
by Saxo
#GLENMARK #SANOFI #PFIZER #BPLPHARMA #MARKSANS #BIOCON #GRANULES#GLENMARK NSE: GLENMARK CMP: 440 TP: 515 SL: 400 TF: <6m RR > 2 times Return > 17% THYROCARE CNXPHARMA LUPIN NSE:CIPLA SUNPHARMA SPARC DIVISLAB DRREDDY AUROPHARMA BALPHARMA GLENMARK SANOFI PFIZER BPLPHARMA MARKSANS BIOCON GRANULES IPCALAB LAURUSLABS NATCOPHARM GLAND ALKEM ZYDUSLIFE Factors: BULLISH WEDGE BREAKOUT Trend Following Rising Volume with rising Prices. Flag pattern breakout. Pennant Pattern Breakout with Bullish Candle. Retest Successful. Higher Highs & Higher Lows. Broken above RESISTANCE levels Trading at SUPPORT levels Earnings are strong. Bullish Wedge Breakout Risk Return Ratio is healthy. And Rising from Double Bottom Pattern to Flag Pattern forming. If you like my work KINDLY LIKE SHARE & FOLLOW this page for free Stock Recommendations. With 💚 from Rachit Sethia
NSE:GLENMARKLong
by Rachit_Sethia
#CIPLA #BALPHARMA #GLENMARK #SANOFI #PFIZER #AUROPHARMA #NIFTY50#CIPLA NSE: CIPLA CMP: 1128 TP: 1250 SL: 1080 TF: <6m RR > 2.5 times Return > 11% THYROCARE CNXPHARMA LUPIN NSE: CIPLA SUNPHARMA SPARC DIVISLAB DRREDDY AUROPHARMA BALPHARMA GLENMARK SANOFI PFIZER Factors: BULLISH WEDGE BREAKOUT Trend Following Rising Volume with rising Prices. Flag pattern breakout. Pennant Pattern Breakout with Bullish Candle. Retest Successful. Higher Highs & Higher Lows. Broken above RESISTANCE levels Trading at SUPPORT levels Earnings are strong. Bullish Wedge Breakout Risk Return Ratio is healthy. And Rising from Double Bottom Pattern to Flag Pattern forming. If you like my work KINDLY LIKE SHARE & FOLLOW this page for free Stock Recommendations. With 💚 from Rachit Sethia
NSE:CIPLALong
by Rachit_Sethia
7
Buying Sanofi break of resistance.Sanofi - 30d expiry - We look to Buy a break of 88.41 (stop at 84.78) Previous resistance level of 83 broken. Short term bias has turned positive. 88.34 has been pivotal. A break of the recent high at 88.34 should result in a further move higher. Prices have reacted from 81.93. Overnight losses have been limited. Our outlook is bullish. Our profit targets will be 97.48 and 99.48 Resistance: 88.40 / 91.00 / 95.00 Support: 86.00 / 84.00 / 82.00 Disclaimer – Saxo Bank Group. Please be reminded – you alone are responsible for your trading – both gains and losses. There is a very high degree of risk involved in trading. The technical analysis , like any and all indicators, strategies, columns, articles and other features accessible on/though this site (including those from Signal Centre) are for informational purposes only and should not be construed as investment advice by you. Such technical analysis are believed to be obtained from sources believed to be reliable, but not warrant their respective completeness or accuracy, or warrant any results from the use of the information. Your use of the technical analysis , as would also your use of any and all mentioned indicators, strategies, columns, articles and all other features, is entirely at your own risk and it is your sole responsibility to evaluate the accuracy, completeness and usefulness (including suitability) of the information. You should assess the risk of any trade with your financial adviser and make your own independent decision(s) regarding any tradable products which may be the subject matter of the technical analysis or any of the said indicators, strategies, columns, articles and all other features. Please also be reminded that if despite the above, any of the said technical analysis (or any of the said indicators, strategies, columns, articles and other features accessible on/through this site) is found to be advisory or a recommendation; and not merely informational in nature, the same is in any event provided with the intention of being for general circulation and availability only. As such it is not intended to and does not form part of any offer or recommendation directed at you specifically, or have any regard to the investment objectives, financial situation or needs of yourself or any other specific person. Before committing to a trade or investment therefore, please seek advice from a financial or other professional adviser regarding the suitability of the product for you and (where available) read the relevant product offer/description documents, including the risk disclosures. If you do not wish to seek such financial advice, please still exercise your mind and consider carefully whether the product is suitable for you because you alone remain responsible for your trading – both gains and losses.
EURONEXT:SANLong
by Saxo
Buying Sanofi correction higher.Sanofi - Intraday - We look to Buy a break of 83.71 (stop at 79.98) We are trading at oversold extremes. Bullish divergence can be seen on the daily (the chart makes a lower low while the oscillator makes a higher low), often a signal of exhausted bearish momentum, or at least a correction higher. 83.58 has been pivotal. A break of 83.60 is needed to confirm follow through bullish momentum. Although the bears are in control, the stalling negative momentum indicates a turnaround is possible. Posted a Double Bottom formation. Further upside is expected, however, due to the strong resistance above we prefer to buy a break of 83.70, which will confirm the bullish sentiment. Our profit targets will be 92.69 and 95.69 Resistance: 83.00 / 87.50 / 90.00 Support: 80.00 / 77.00 / 75.00 Disclaimer – Saxo Bank Group. Please be reminded – you alone are responsible for your trading – both gains and losses. There is a very high degree of risk involved in trading. The technical analysis , like any and all indicators, strategies, columns, articles and other features accessible on/though this site (including those from Signal Centre) are for informational purposes only and should not be construed as investment advice by you. Such technical analysis are believed to be obtained from sources believed to be reliable, but not warrant their respective completeness or accuracy, or warrant any results from the use of the information. Your use of the technical analysis , as would also your use of any and all mentioned indicators, strategies, columns, articles and all other features, is entirely at your own risk and it is your sole responsibility to evaluate the accuracy, completeness and usefulness (including suitability) of the information. You should assess the risk of any trade with your financial adviser and make your own independent decision(s) regarding any tradable products which may be the subject matter of the technical analysis or any of the said indicators, strategies, columns, articles and all other features. Please also be reminded that if despite the above, any of the said technical analysis (or any of the said indicators, strategies, columns, articles and other features accessible on/through this site) is found to be advisory or a recommendation; and not merely informational in nature, the same is in any event provided with the intention of being for general circulation and availability only. As such it is not intended to and does not form part of any offer or recommendation directed at you specifically, or have any regard to the investment objectives, financial situation or needs of yourself or any other specific person. Before committing to a trade or investment therefore, please seek advice from a financial or other professional adviser regarding the suitability of the product for you and (where available) read the relevant product offer/description documents, including the risk disclosures. If you do not wish to seek such financial advice, please still exercise your mind and consider carefully whether the product is suitable for you because you alone remain responsible for your trading – both gains and losses.
EURONEXT:SANLong
by Saxo
Sanofi - Pharming for profits?Sanofi Short Term We look to Buy at 95.00 (stop at 91.90) The medium term bias remains bullish. Levels close to the 50% pullback level of 93.25 found buyers. Previous support located at 93.08. Further upside is expected and we look to set longs in early trade. Our profit targets will be 104.35 and 110.00 Resistance: 95.16 / 98.22 / 104.35 Support: 93.25 / 93.08 / 92.78 Disclaimer – Saxo Bank Group. Please be reminded – you alone are responsible for your trading – both gains and losses. There is a very high degree of risk involved in trading. The technical analysis, like any and all indicators, strategies, columns, articles and other features accessible on/though this site (including those from Signal Centre) are for informational purposes only and should not be construed as investment advice by you. Such technical analysis are believed to be obtained from sources believed to be reliable, but not warrant their respective completeness or accuracy, or warrant any results from the use of the information. Your use of the technical analysis, as would also your use of any and all mentioned indicators, strategies, columns, articles and all other features, is entirely at your own risk and it is your sole responsibility to evaluate the accuracy, completeness and usefulness (including suitability) of the information. You should assess the risk of any trade with your financial adviser and make your own independent decision(s) regarding any tradable products which may be the subject matter of the technical analysis or any of the said indicators, strategies, columns, articles and all other features. Please also be reminded that if despite the above, any of the said technical analysis (or any of the said indicators, strategies, columns, articles and other features accessible on/through this site) is found to be advisory or a recommendation; and not merely informational in nature, the same is in any event provided with the intention of being for general circulation and availability only. As such it is not intended to and does not form part of any offer or recommendation directed at you specifically, or have any regard to the investment objectives, financial situation or needs of yourself or any other specific person. Before committing to a trade or investment therefore, please seek advice from a financial or other professional adviser regarding the suitability of the product for you and (where available) read the relevant product offer/description documents, including the risk disclosures. If you do not wish to seek such financial advice, please still exercise your mind and consider carefully whether the product is suitable for you because you alone remain responsible for your trading – both gains and losses.
EURONEXT:SANLong
by Saxo
SNY Fib Levels On The Radar & WhySNY and TBIO buttoned up the news this morning sending a bunch of other biotech stocks running higher. Now that this is out of the way, levels could be important for longs looking for "what's next" and the 236 Fib level seems to be that area to watch. It was an area that the volatile SNY stock settled above for weeks and now is an area it hasn't been able to break above for the last several weeks. Heading into the month after this acquisition, it's gonna be interesting to see if mRNA stocks start to catch a bit more. " A mega buyout from Sanofi (NASDAQ: SNY) has investors looking at biotech stocks today. If you remember our article, “Top Biotech Penny Stocks On Robinhood To Watch This Week,” we discussed Sanofi and its strengthening relationship with a former penny stock, Translate Bio Inc. (NASDAQ: TBIO)...Sanofi had previously pledged to invest 400 million euros annually in a vaccines R&D facility to advance mRNA vaccines with Translate to benefit. Tuesday, Sanofi formally announced a $3.2 billion buyout of its vaccine collaboration partner. This was at $38 a share in cash, roughly 30% higher than the close on August 2nd. " Quote Source & Read More: Hot Biotech Stocks To Watch After Sanofi’s Acquisition Of Translate Bio
NASDAQ:SNY
by PennyStocks101